Identifying Novel Therapeutic Combinations with 131I-MIBG to Treat Relapsed and Refractory Neuroblastoma |
The Regents of the University of California San Francisco / William Clay Gustafson, M.D., Ph.D. |
Reach Grants |
2014 |
California |
LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma |
University of Virginia, School of Medicine / Michael Engel, MD/PhD |
Reach Grants |
2016 |
Virginia |
Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma |
City of Hope National Medical Center / Linda Malkas, PhD |
Reach Grants |
2019 |
California |
Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma
|
Duke University Medical Center / Gerard Blobe, MD, PhD |
Reach Grants |
2013 |
North Carolina |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG |
Mayo Clinic / David Daniels, MD/PhD |
Reach Grants |
2021 |
Minnesota |
Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion |
Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD |
Reach Grants |
2019 |
Ohio |
Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma
|
Beckman Research Institute of City of Hope / Margarita Gutova, MD |
Reach Grants |
2013 |
California |
Novel Genomic Diagnostics for Intracranial Germ Cell Tumors |
Connecticut Children’s Medical Center Foundation, Inc. / Ching Lau, MD/PhD |
Reach Grants |
2021 |
Connecticut |
Moving EphB4 Therapeutics to Pediatric Phase I/II Trials |
Oregon Health & Science University / Charles Keller, MD |
Reach Grants |
2013 |
Oregon |
Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma |
Baylor College of Medicine / Cliona Rooney, PhD |
Reach Grants |
2013 |
Texas |